The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids

Journal of Obstetrics and Gynaecology

Volumn 18, Issue 2, 1998, Pages 141-145

  Bhathena, R K ^a,c   Anklesaria, B S ^a,b   Ganatra, A M ^b   Pinto, Rosaline ^b  

^a T/7e Menopause Clinic   (India)

^b Medical College   (India)

^c Petit Parsee General and Masina Hospitals   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEPRATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031943714     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443619867885     Document Type: Article

References (32)

1. Adami S., Rossini M., Zamberlan N., Bertoldo F., Dorizzi R. and Lo Cascio V. (1993) Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas, 17, 191-196.
2. Barrett-Connor E. and Bush T. L. (1991) Estrogen and coronary heart disease in women. Journal of the American Medical Association, 265, 1861-1867.
3. Basdevant A., DeLigneres B. and Guy-Grand B. (1983) Differential lipaemic and hormonal responses to oral and parenteral 17 beta-oestradiol in postmenopausal women. American Journal of Obstetrics and Gynaecology, 147, 77-81.
4. Bengtsson C., Bjorkelund C., Lapidus L. and Lissner L. (1993) Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow-up of participants in prospective population study in Gothenberg, Sweden. British Medical Journal, 307, 1385-1388.
5. Castelli W. P. (1986) The triglycéride issue: a view from Framingham. American Heart Journal, 112, 43237.
6. Crook D., Gust M. P., Gangar K. F. and Stevenson J. C. (1992) Comparison of transdermal and oral estrogenprogestin replacement therapy: effects on serum lipids and lipoproteins. American Journal of Obstetrics and Gynaecology, 166, 950-955.
7. Crook D., Godsland I. F. and Stevenson J. C. (1995) The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. European Menopause Journal, 2, 23-30.
8. Crook D. and Stevenson J. C. (1996) Transdermal hormone replacement therapy, serum lipids and lipoproteins. British Journal of Clinical Practice Supplement, 86, 17-21.
9. Erenus M., Kutlay K., Kutlay L. and Pékin S. (1994) Comparison of the impact of oral versus transdermal estrogen on serum lipoproteins. Fertility and Sterility, 61, 300-302.
10. Erkkola R. U., Hirvonen E. J., Juntunen K. S. T., Saastamoinen J. A., Tuimala R. J., Rinne R. M. and Paakkari A. T. I. (1995) Comparison of transdermal to oral hormone replacement therapy-effects on lipid and carbohydrate metabolism, and on antithrombin III, fibrinogen, renin substrate and .sex hormone binding globulin. European Menopause Journal, 2, 21-27.
11. Falkeborn M., Persson I. and Adami H. (1992) The risk of acute myocardial infarction after oestrogen-progestin replacement. British Journal of Obstetrics and Gynaecology, 99, 821-828.
12. Friedewald W. T., Levy R. I. and Fredrickson D. S. (1972) Estimation of the concentration of LDL-cholesteroI in plasma without the use of preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
13. Gevers Leuven J. A., van der Mooren M. J. and Buytenhek R. (1995) The effect of medrogestone on plasma lipids in postmenopausal women using conjugated oestrogens: an open randomised comparative study. Fertility and Sterility, 64, 525-531.
14. Hirvonen E., Malkonen M. and Manninen V. (1981) Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. New England Journal of Medicine, 304, 560-563.
15. Jacobs D. R., Mebane I. L., Bangdiwala S. L, Criqui M. H. and Tyroler H. A. (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipids Research Clinics prevalence study. American Journal of Epidemiology, 131, 32-47.
16. Lobo R. A. and Speroff L. (1994) International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertility and Sterility, 61, 592595.
17. Matthews K. (1989) Menopause and risk factors for coronary heart disease. New England Journal of Medicine, 321, 641-646.
18. Mattsson L., Samsioe G., von-SchouItz B., Uvebrant M. and Wiklund I. (1993) Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. British Journal of Obstetrics and Gynaecology, 100, 450-453.
19. Mijatovic V. (1995) Ageing menopausal women, cardiovascular disease and HRT. European Menopause Journal, 2 (2), 28-30.
20. Mijatovic V. and Pines A. (1995) Menopause-induced changes in cardiovascular functions and HRT. European Menopause Journal, 2(1), 4-9.
21. Pang S., Greendale G., Cedars M., Gambone J., Lozano K., Eggena P. and Judd H. (1993) Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertility and Sterility, 59, 76-82.
22. Schräm J. H. N., Boerrigter P. J. and The T. Y. (1995) Influence of two HRT regimens: oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. Maturitas, 22, 121-130.
23. Stampfer M. J., Colditz G. A., Willett \V. C., Manson J. E., Rosner B., Speizer F. E. and Hennekens E. H. (1991) Postmenopausal oestrogen therapy and cardiovascular disease. New England Journal of Medicine, 325, 756-762.
24. Stanczyk F. Z., Shoupe D., Nunez V., Macias-Gonzales P., Vijod M. and Lobo R. (1988) A randomised comparison of non-oral estradiol delivery in postmenopausal women. American Journal of Obstetrics and Gynaecology, 159, 1540-1546.
25. Stevenson J. C., Crook D. and Godsland I. F. (1993) Effects of age and menopause on lipid metabolism in healthy women. Atherosclerosis, 98, 83-90.
26. Stevenson J. C., Crook D., Godsland I. F., Collins P. and Whitehead M. I. (1994) Hormone replacement therapy and the cardiovascular system: non-lipid effects. Drugs, 47, 35-41.
27. The Writing Group of the PEPI Trial (1995), Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Journal of the American Medical Association, 273, 199-208.
28. Walsh B. W., Schiff L, Rosner B., Greenburg L., Ravnikar V. and Sacks F. M. (1991) Effects of postmenopausal estrogen replacement on concentration and metabolism of plasma lipoproteins. New England Journal of Medicine, 325, 1196-1204.
29. Whitcroft S. I., Crook D., March M. S., Ellerington M. C., Whitehead M. I. and Stevenson J. C. (1994) Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstetrics and Gynaecology, 84, 222-226.
30. Whitehead M. I., Fräser D., Schenkel L., Crook D. and Stevenson J. C. (1990) Transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet, 335, 310-312.
31. Whitehead M. I. (1994) Progestins and androgens. Fertility and Sterility Supplement, 62, 161S-167S.
32. Wiseman L. R. and McTavish D. (1994) Transdermal estradiol/norethisterone,-a review of its pharmacological properties and clinical use in postmenopausal women. Drugs and Aging, 4, 238-256.